Weekly update|Companies|Recruiting|Promote|Post a job

Vanqua Bio

Founded: 2019

Location: Chicago, IL

Employee range: 11 - 50

Clinical stage: Clin0

Therapy area: Parkinson's, Gaucher disease

Drug types: NEU

Lead product: Undisclosed

Product link: https://www.vanquabio.com/science/

Funding: $85M B Sep 2021

Investors: OrbiMed, Omega Funds, Surveyor Capital, Avoro Ventures, Casdin Capital, Pontifax, Eli Lilly, Logos Capital, Osage University Partners

vanquabio.com

linkedin.com

job board

Short description:

Small Molecules Targeting Neuro Indications

Drug notes:

Also RD Parkinson's, Lewy body dementia; 2 additional undisclosed programs RD Alzheimer's, Parkinson's, neurodegenerative diseases

Long description:

Vanqua Bio utilizes our knowledge of lysosomal biology and the immune system, along with an iPSC-derived neuronal cell screening platform to find treatments for neurodegenerative diseases. They aim to develop disease-modifying therapies rather than treating symptoms, as current neurodegenerative treatments do. This approach has the potential to slow or stop the progression of these neurological diseases like Alzheimer’s and Parkinson’s disease. Vanqua is targeting lysosomal function and the complement pathway of the immune system to achieve their goals, both having aberrant activity in various neurodegenerative diseases. These therapeutics hold promise for those with debilitating neurological disorders that currently have limited treatment options.

Jobs:

Main

Contact: recruit@workinbiotech.com